| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 2 | 0 | 2 | 77 | 95 | 107 | 135 | 126 | 130 | 107 | 120 | 122 |
| Expenses | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 134 | 105 | 99 | 101 |
| EBITDA | -1 | -3 | -0 | 3 | 7 | 5 | 11 | 2 | -4 | 1 | 22 | 21 |
| Operating Profit % | -110 % | -1,759 % | -67 % | 3 % | 6 % | 4 % | 6 % | 1 % | -4 % | -0 % | 17 % | 15 % |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Interest | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 5 |
| Profit Before Tax | -2 | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -7 | 14 | 13 |
| Tax | 0 | 0 | -0 | -0 | 0 | -0 | 0 | -1 | -3 | -2 | 4 | -0 |
| Net Profit | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -5 | 10 | 9 |
| EPS in ₹ | -2.31 | -5.49 | -1.26 | 1.14 | 2.64 | 0.33 | 1.08 | -0.78 | -1.98 | -1.12 | 2.03 | 1.90 |
Kimia Biosciences
Kimia Biosciences
35.50
-35.42
(-100.00%)
Market Cap
167.60 Cr
EPS
2.03
PE Ratio
19.04
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
86.85
52 Week Low
34.25
PB Ratio
16.82
Debt to Equity
7.46
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Kimia Biosciences Limited, an Indian pharmaceutical company, reported total income of ₹6,103 lakhs for the quarter ended June 30, 2025, representing a 1.61% year-over-year decline but a 20.18% quarter-over-quarter increase. Net profit reached ₹613 lakhs, down 1.13% compared to the same quarter last year but up 6.06% sequentially. Earnings per share stood at ₹4.31, declining 2.05% year-over-year while improving 6.42% quarter-over-quarter. The company published its unaudited standalone financial results in English and Hindi newspapers as required by regulatory compliance.
Kimia Biosciences Limited's Board of Directors approved unaudited standalone financial results for the quarter ended June 30, 2025. The company appointed Mr. Pradip Kumar Sharma as Chief Financial Officer with immediate effect. Sharma brings over 10 years of experience in finance, accounting, taxation and treasury management, having held senior leadership positions in several listed companies. The Board also approved raising an unsecured loan of ₹2 crores at 8% per annum interest rate. Additionally, the Board noted and discussed a warning letter dated July 25, 2025 received from BSE Limited.
Kimia Biosciences Shareholders Approve Statutory Auditor and Director Appointments in EGMJul 24, 2025
Kimia Biosciences Limited conducted an Extra-Ordinary General Meeting on July 22, 2025, where shareholders voted on two key resolutions through remote e-voting and during the meeting. The company appointed Mrs. Surbhi Bansal as scrutinizer to oversee the voting process. Both resolutions were passed with requisite majority: Resolution 1 for regularization of M/s Neeraj Arora & Associates as Statutory Auditors received 99.74% approval from valid votes cast, while Resolution 2 for regularization of Mr. Prasad Raju as Additional Director received 99.73% approval. Out of 12,523 total shareholders on record, 76 members participated in voting, with 53 attending through video conferencing. The promoter group voted entirely in favor of both resolutions, while public non-institutional shareholders showed mixed voting patterns with significant opposition votes of 92,332 and 95,320 respectively for the two resolutions.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,636.20 | #1 3,92,579.20 | 34.22 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 43.29 | |
5,710.00 | 1,51,582.60 | 65.74 | 9,712.00 | 18.67 | 2,191 | 26.74 | 28.97 | |
1,513.00 | 1,22,213.20 | 22.68 | 28,409.50 | 7.12 | 5,291 | 9.88 | 39.80 | |
3,567.10 | 1,20,726.90 | 59.71 | 11,539.40 | 6.99 | 1,911 | 19.91 | 51.91 | |
1,244.70 | 1,03,884.40 | #1 18.31 | 33,741.20 | 16.73 | 5,725 | 1.26 | 34.86 | |
2,439.60 | 1,00,696.60 | 53.25 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 34.79 | |
991.15 | 99,732.90 | 21.41 | 23,511.00 | 18.55 | 4,615 | 2.60 | 40.31 | |
1,981.30 | 90,496.80 | 24.47 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 38.96 | |
5,459.50 | 65,276.50 | 28.71 | 13,458.30 | 3.70 | 2,216 | 21.39 | 52.88 | |
29,890.00 | 63,514.20 | 43.71 | 6,684.70 | 9.64 | 1,414 | 11.55 | 25.66 |
Forecast
Actual
Growth Rate
Revenue Growth
12.86 %
Net Income Growth
-281.13 %
Cash Flow Change
46.66 %
ROE
-106.01 %
ROCE
-985.55 %
EBITDA Margin (Avg.)
1,545.87 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 110 | 121 | 100 | 111 |
| Fixed Assets | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | 33 |
| Current Assets | 1 | 1 | 2 | 43 | 48 | 61 | 72 | 73 | 83 | 61 | 75 |
| Capital Work in Progress | 0 | 0 | 3 | 3 | 2 | 6 | 6 | 0 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1 | 1 | 2 | 43 | 48 | 62 | 73 | 74 | 87 | 68 | 78 |
| Total Liabilities | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 110 | 121 | 100 | 111 |
| Current Liabilities | 4 | 1 | 7 | 31 | 30 | 39 | 51 | 62 | 76 | 69 | 82 |
| Non Current Liabilities | 1 | 7 | 9 | 25 | 29 | 34 | 37 | 33 | 40 | 30 | 19 |
| Total Equity | 0 | -4 | -5 | 2 | 6 | 13 | 18 | 15 | 6 | 0 | 10 |
| Reserve & Surplus | -7 | -11 | -12 | -2 | 2 | 9 | 14 | 10 | 1 | -4 | 5 |
| Share Capital | 7 | 7 | 7 | 2 | 2 | 5 | 5 | 5 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 0 | 1 | -1 | 0 | 0 | -0 | 0 | 0 | 0 |
| Investing Activities | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | -2 | -5 |
| Operating Activities | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | 15 | 21 |
| Financing Activities | -0 | 6 | 7 | 10 | 4 | 9 | 8 | -8 | 10 | -13 | -17 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % | 74.94 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % | 0.38 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 23.16 % | 23.15 % | 23.15 % | 23.09 % | 23.16 % | 0.00 % | 23.20 % | 23.11 % | 23.10 % | 23.04 % | 23.04 % | 23.04 % | 23.05 % | 23.05 % | 23.03 % | 22.94 % | 23.04 % | 23.04 % |
| Others | 1.52 % | 1.52 % | 1.52 % | 1.59 % | 1.51 % | 24.68 % | 1.48 % | 1.57 % | 1.58 % | 1.64 % | 1.64 % | 1.64 % | 1.63 % | 1.63 % | 1.65 % | 1.74 % | 1.64 % | 1.64 % |
| No of Share Holders | 11,912 | 12,192 | 12,173 | 12,212 | 12,510 | 12,454 | 12,399 | 12,243 | 12,201 | 12,147 | 12,118 | 12,063 | 12,110 | 12,023 | 12,179 | 12,231 | 12,278 | 12,200 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 04 Jan 2019 |  Change Of Name | NA | 04 Jan 2019 | 39.90 | 39.90 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 48.72 | 46.88 |
| 30 Dec 2025 |  Annual General Meeting | NA | 30 Dec 2025 | 49.79 | 45.00 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 47.04 | 43.25 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 40.50 | 42.10 |
| 22 Jul 2025 |  Extraordinary General Meeting | NA | 22 Jul 2025 | 50.41 | 70.47 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 46.31 | 43.00 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 37.93 | 37.35 |
Announcements
Shareholder Meeting / Postal Ballot-Scrutinizers Report
1 day ago
1 day agoIntimation-Change Of Scrutiniser Due To Unavailability-AGM On 30Th September 2025.1 day ago
1 day agoShareholder Meeting / Postal Ballot-Outcome of AGM2 days ago
2 days agoShareholder Meeting / Postal Ballot-Outcome of AGM2 days ago
2 days agoClosure of Trading Window6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2025
Sep 06, 2025Intimation Of Book Closure/Record Date/E-Voting For The 32Nd Annual General MeetingSep 06, 2025
Sep 06, 2025Reg. 34 (1) Annual Report.Sep 06, 2025
Sep 06, 2025Intimation Of 32Nd Annual General Meeting Of The Company Proposed To Be Held On September 30 2025 At 4:00 P.M. Through Video Conferencing/Other Audio Visual Means.Sep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Sep 05, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 29.08.2025Aug 29, 2025
Aug 29, 2025Board Meeting Intimation for Board Meeting To Be Held On Friday August 29 2025Aug 26, 2025
Aug 26, 2025Revised Outcome Of Board Meeting Dated 14.08.2025Aug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2025
Aug 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Board Meeting Outcome for Board Meeting Outcome For Board Meeting Held Today On 14 Auguest2025Aug 14, 2025
Aug 14, 2025Financial Results For The Quarter Ended June 30 2025Aug 14, 2025
Aug 14, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 On Thursday August 14 2025 At 12:00 P.M.Aug 08, 2025
Aug 08, 2025Disclosure under Regulation 30A of LODRAug 04, 2025
Aug 04, 2025Disclosure under Regulation 30A of LODRJul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 24, 2025
Jul 24, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMJul 23, 2025
Jul 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025ANNOUNCEMENT UNDER REGULATION 30(LODR) REGARDING THE CLARIFICAION -PRICE MOVEMENTJul 02, 2025
Jul 02, 2025Clarification sought from Kimia Biosciences LtdJul 02, 2025
Jul 02, 2025Intimation Of Newspaper Advertisement Of Extraordinary General Meeting And E-Voting Information.
Jul 01, 2025
Jul 01, 2025NOTICE OF EXTRA-ORDINARY GENERAL MEETING OF KIMIA BIOSCIENCES LIMITEDJun 29, 2025
Jun 29, 2025Intimation Of Extra-Ordinary General Meeting Scheduled To Be Held On 22 July2025Jun 29, 2025
Jun 29, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025INTIMATION FOR THE APPOINTMENT OF INTERNAL AUDITOR FOR THE FINANCIAL YEAR 2025-2026Jun 25, 2025
Jun 25, 2025INTIMATION FOR THE APPOINTMENT OF SECRETARIAL AUDITOR FOR THE FINANCIAL YEAR 2024-2025Jun 25, 2025
Jun 25, 2025INTIMATION FOR THE APPOINTMENT OF ADDITIONAL DIRECTOR REGULARISATION WILL BE DONE IN ENSUING EGM SCHEDULED TO BE HELD ON 22 JULY2025Jun 25, 2025
Jun 25, 2025INTIMATION FOR THE APPOINTMENT OF COST AUDITORJun 25, 2025
Jun 25, 2025Disclosure under Regulation 30A of LODRJun 25, 2025
Jun 25, 2025Disclosure under Regulation 30A of LODRJun 25, 2025
Jun 25, 2025Disclosure under Regulation 30A of LODRJun 25, 2025
Jun 25, 2025Disclosure under Regulation 30A of LODRJun 25, 2025
Jun 25, 2025Board Meeting Outcome for Board Meeting Outcome As Per Regulation 30SEBI(LODR)Jun 25, 2025
Jun 25, 2025Reg. 34 (1) Annual Report.Jun 24, 2025
Jun 24, 2025Detailed Reasons For Delay In Submission Of Financial Results For Period/Year Ended March 31 2025.
With Reference To The Communication Regarding The Delay In Submitting The Financial Results For The Quarter And Financial Year Ended On 31St March 2025 DatJun 23, 2025
Jun 23, 2025 INTIMATION OF BOARD MEETING UNDER REGULATION 29(1)(D) OF SEBI (LODR) REGULATIONS2015Jun 20, 2025
Jun 20, 2025Revised Board Meeting Outcome Held On 26 May2025 Document For The Quarter And Financial Year Ended On 31St March 2025 (Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements)Regulations 2015Jun 12, 2025
Jun 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Non-Applicability Of Regulation 24A Of SEBI(Listing Obligation And Disclosure )Regulations2015May 29, 2025
May 29, 2025Financial Results Ended On 31 March 2025May 28, 2025
May 28, 2025Newspaper Publication Of Financial Results As Per Regulation 30 Of Securities Exchange Board Of India2015May 28, 2025
May 28, 2025Integrated Filing (Financial)May 26, 2025
May 26, 2025Board Meeting Outcome for Outcome Of The Financials In The Board MeetingMay 26, 2025
May 26, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AMay 23, 2025
May 23, 2025Board Meeting Intimation for Approval Of Audited Financials For The Quarter And Financial Year Ended On 31St March 2025May 21, 2025
May 21, 2025Technical Indicators
RSI(14)
Neutral 39.87
ATR(14)
Less Volatile 2.10
STOCH(9,6)
Neutral 44.47
STOCH RSI(14)
Neutral 76.73
MACD(12,26)
Bullish 0.56
ADX(14)
Strong Trend 27.26
UO(9)
Bearish 47.35
ROC(12)
Downtrend And Accelerating -1.58
WillR(14)
Neutral -76.36
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
